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Editor: Mohandas NarlaTaliglucerase alfa, the ﬁrst available plant cell–expressed recombinant therapeutic protein, is an enzyme re-
placement therapy approved for Gaucher disease (GD). PB-06-001, a pivotal phase 3, multicenter, random-
ized, double-blind, parallel-dose study investigated taliglucerase alfa 30 or 60 U/kg every other week
through 9 months in treatment-naïve adults with GD; 30-month extension study PB-06-003 followed. Pa-
tients completing PB-06-001 and PB-06-003 could continue treatment in PB-06-007. Nineteen patients en-
rolled in PB-06-007 (30 U/kg, n = 8; 60 U/kg, n = 9; dose adjusted, n = 2); 17 completed 5 total years of
treatment. In these 3 groups, respectively, taliglucerase alfa resulted in mean decreases in spleen volume
(−8.7, −6.9, −12.4 multiples of normal), liver volume (−0.6, −0.4, −0.5 multiples of normal),
chitotriosidase activity (−83.1%, −93.4%, −87.9%), and chemokine (C\\C motif) ligand 18 concentration
(−66.7%,−83.3%,−78.9%), as well as mean increases in hemoglobin concentration (+2.1, +2.1, +1.8 mg/dL)
and platelet count (+31,871, +106,800, +34,000/mm3). The most common adverse events were
nasopharyngitis and arthralgia. Most adverse events weremild/moderate; no serious adverse eventswere consid-
ered treatment-related. These results demonstrate continued improvement of disease parameters during 5 years
of taliglucerase alfa therapy in 17 treatment-naive patients with no new safety concerns, extending the
taliglucerase alfa clinical efﬁcacy and safety dataset. This study was registered at www.clinicaltrials.gov as
NCT01422187.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The rare lysosomal storage disorder Gaucher disease (GD) is caused
by mutations in the gene for the enzyme beta-glucocerebrosidase [1].
These mutations confer deﬁcient activity of beta-glucocerebrosidase in
macrophages and other cell types, resulting in lysosomal accumulation
of glucocerebroside and leading to pathology that includes splenomeg-
aly, hepatomegaly, anemia, and thrombocytopenia [1].
GD exists as a spectrum of disease with 3 major phenotypes:
nonneuronopathic Type 1, acute neuronopathic Type 2, and chronic
neuronopathic Type 3 [2]. The most common form is Type 1 GD; it
can manifest at any age, from infancy through adulthood [3,4].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
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tients with GD [5,6]. Taliglucerase alfa is an ERT approved for the treat-
ment of adult patients with Type 1 GD in the United States, Israel, Brazil,
Australia, Canada, Chile, and other countries, and is approved for the
treatment of pediatric patients in the United States, Australia, Canada,
Israel, Mexico, and other countries, and for hematologic manifestations
of Type 3 GD in pediatric patients in Canada. Taliglucerase alfa is free of
mammalian components, is produced in disposable bioreactors, and is
the ﬁrst plant cell–expressed recombinant therapeutic protein ever ap-
proved by the US Food and Drug Administration (FDA) for use in
humans [7–9].
A phase 3, multicenter, randomized, double-blind, parallel-dose
study (NCT00376168; Study PB-06-001) investigated treatment
with taliglucerase alfa 30 U/kg or 60 U/kg through 9 months in treat-
ment-naïve adult patients with GD [10]. In this initial pivotal study,
patients demonstrated improvements in spleen and liver volume,
hemoglobin concentration, platelet counts, and chitotriosidase ac-
tivity with taliglucerase alfa 30 U/kg and 60 U/kg [10]. Treatment-
related adverse events (AEs) were all mild or moderate in intensity,
and no serious AEs were reported [10].
Patients who continued into extension study PB-06-003
(NCT00705939) demonstrated continued improvement in the disease
parameters, and no new safety issues emerged [11,12]. Patients who
completed Study PB-06-003 were eligible to continue treatment in an
additional extension study, PB-06-007, for a total duration of treatment
with taliglucerase alfa of up to 5 years. This report presents the efﬁcacy
and safety results for treatment-naïve adult patients with GD who re-
ceived taliglucerase alfa at a dose of 30 U/kg or 60 U/kg for up to 5
total years of treatment.
2. Materials and methods
2.1. Study design
Patients were enrolled in extension study PB-06-007 (NCT-
01422187) after sequentially completing studies PB-06-001 and
PB-06-003, representing 39 total months of treatment. Details of
PB-06-001 and PB-06-003 have previously been reported [10–12].
In PB-06-007, patients continued to receive further treatment with
taliglucerase alfa at the same dose, for an additional 21 months
(total of 60 months), or until taliglucerase alfa became commercially
available, at the discretion of the sponsor.
The protocol and the informed consent form were approved by the
appropriate ethics committee and institutional review board associated
with each study site. The studywas conducted in accordancewith Good
Clinical Practice guidelines according to the International Council on
Harmonisation Harmonised Tripartite Guideline and all local regula-
tions. All patients provided written informed consent before study
participation.
2.2. Patients
Patients had to meet the following criteria for inclusion in PB-06-
001 [10]: aged ≥18 years with GD, naïve to ERT or no ERT in the past
12 months, and negative anti-glucocerebrosidase antibody test;
splenomegaly, deﬁned as spleen volume ≥ 8 times the normal vol-
ume expected based on body weight; and thrombocytopenia, de-
ﬁned as a platelet count b120,000/mm3 with or without anemia.
Exclusion criteria for PB-06-001 included presence of signs and
symptoms characteristic of neuronopathic GD and previous anaphy-
lactoid reaction to alglucerase or imiglucerase and use of another ex-
perimental drug (for any disease) and presence of any medical,
emotional, behavioral, or psychological condition that in the judg-
ment of the investigator would interfere with the patient's compli-
ance with the requirements of the study. Patients had to have
completed PB-01-001 and PB-06-003 to be included in PB-06-007.Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016Exclusion criteria for PB-06-007 included current use of another in-
vestigational drug for any condition and presence of any medical,
emotional, behavioral, or psychological condition that, in the judg-
ment of the investigator, would interfere with the patient's compli-
ance with the requirements of the study.
2.3. Treatment
For all patients, taliglucerase alfa was administered intravenously at
2-week intervals at the same dose as the last treatment in PB-06-003;
dose adjustments were allowed.
2.4. Efﬁcacy assessments
Spleen and liver volume were measured by volumetric magnetic
resonance imaging using a validated system and blinded central
readers, as described previously [10,13]. Volumes were expressed as
multiples of normal (MN), where normal spleen volume is 2 mL/kg of
body weight (kg) and normal liver volume is 25 mL/kg of body weight
(kg). Hemoglobin concentration and platelet count were measured
along with the biomarkers of chitotriosidase activity and chemokine
(C\\C motif) ligand 18 (CCL18) concentration. Due to assay variability
and for biomarker measurement consistency, the baseline samples ob-
tained during Study PB-06-001 were re-run with the on-treatment
samples for each time point from studies PB-06-001, PB-06-003, and
PB-06-007 for chitotriosidase activity and CCL18 concentration; pa-
tients who discontinued the study were excluded entirely from bio-
marker analyses.
Measurement of bone marrow fat fraction was performed as an ex-
ploratory endpoint in a subset of the patients who underwent quantita-
tive chemical shift imaging (QCSI) of the lumbar spine, as previously
described [14]. The QCSI measurements were performed during Study
PB-06-007 at 48 and 60 total months of taliglucerase alfa treatment.
Measurements were compared with data from a Dutch GD population
analysis, which demonstrated that mean lumbar spine fat fraction in
healthy persons is approximately 0.37, whereas a fat fraction of ≤0.23
is associated with increased risk of bone complications [15].
2.5. Safety assessments
Safety assessments included the incidence and severity of AEs,
physical examination ﬁndings, clinical laboratory values, electrocar-
diogram (ECG), echocardiogram, and pulmonary function tests.
Anti-taliglucerase alfa antibodies and, in patients who had a positive
antibody response, neutralizing antibodies were assessed using a
validated analytical method.
2.6. Statistical analysis
For each parameter, efﬁcacy analyses included those patients for
whom data were available at each time point. The baseline for efﬁcacy
data was that for the beginning of the original taliglucerase alfa study
(PB-06-001), and time points were counted continuously through PB-
06-007. Change and percent change from baseline were summarized
for spleen volume, liver volume, hemoglobin, platelet counts, and bio-
markers (chitotriosidase and/or CCL18) using descriptive statistics.
Descriptive statistics for continuous variables, sample size,mean and
standard error (SE) of themean (efﬁcacy analysis parameters), standard
deviation (summary demographic parameters), median, and range
were calculated. For categorical variables, count and percentage are pre-
sented. No inferential statistical analyseswere performed for testing the
change from baseline and/or for comparisons between or among treat-
ment groups. Data from 2 patients whose dose was adjusted were ana-
lyzed separately.), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
Fig. 1.Disposition of patients from the end of Study PB-06-003 through the end of extension studyPB-06-007. Two patientswhowere receiving taliglucerase alfa 30U/kg in PB-06-003 had
dose adjustments to 45 U/kg (n = 1) and 60 U/kg (n = 1) after 27 total months of treatment in that study, and their data were analyzed separately for this report. The 2 patients who
discontinued did so prior to any efﬁcacy measurements in Study PB-06-007.
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dose of study drug in PB-06-007. AEs reported here are those that oc-
curred during PB-06-007.Table 1
Baseline patient demographics.
Taliglucerase alfa
30 U/kg
Taliglucerase alfa
60 U/kg
Dose adjustment
(n = 8) (n = 9) (n = 2)
Age, years
Mean (SD) 44.8 (13.4) 39.9 (12.0) 38.5 (0.7)
Median (range) 40.5 (36–77) 37.0 (23–57) a
Sex, n (%)
Male 4 (50.0) 6 (66.7) 1 (50.0)
Female 4 (50.0) 3 (33.3) 1 (50.0)
Race, n (%)
Caucasian 8 (100.0) 9 (100.0) 2 (100.0)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Ethnicity, n (%)
Jewish–Ashkenazi 2 (25.0) 1 (11.1) 1 (50.0)
Non-Jewish 6 (75.0) 8 (88.9) 1 (50.0)
SD, standard deviation.3. Results
Patient disposition is shown in Fig. 1. A total of 19 patients from 9
study sites enrolled in PB-06-007; 8 patients continued receiving
taliglucerase alfa 30 U/kg, 9 patients continued receiving taliglucerase
alfa 60 U/kg, and 2 patients were receiving taliglucerase alfa 30 U/kg
in PB-06-003 and had dose adjustments to 45 U/kg (11-014) and
60 U/kg (42-025) in that study after 27 total months of treatment.
Data for these 2 patients with dose adjustments were analyzed sepa-
rately for this report. A total of 17 patients completed PB-06-007, and
each received taliglucerase alfa infusions for a total of 60 months
(5 years). Two patients discontinued from the study: One patient (40-
017; 30 U/kg) discontinued for personal logistical reasons after receiv-
ing infusions in Study PB-06-007 (41.5 total months of treatment);
the other patient (40-018; 60U/kg)was lost to follow-up after receiving
4 infusions in Study PB-06-007 (41.3 total months of treatment). The
patients discontinued prior to any efﬁcacy measurements in PB-06-
007; their efﬁcacy in Study PB-06-003 is reported elsewhere [11,12].
Baseline patient demographics are shown in Table 1, and baseline dis-
ease characteristics are shown in Table 2. Individual patientPlease cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016demographics, dose, duration of treatment, and baseline disease param-
eters are listed in Supplementary Tables S1–3.a Median not applicable for n = 2.
), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
Table 2
Baseline a disease characteristics.
Taliglucerase alfa 30 U/kg Taliglucerase alfa 60 U/kg Dose adjustment
(n = 8) (n = 9) (n = 2)
Spleen volume, MN
Mean (SE) 14.5 (3.1) 15.8 (4.9) 19.8 (8.2)
Median (range) 12.1 (7.7b–34.5) 10.7 (7.8b–54.2) (11.6; 28.0)c
Liver volume, MN
Mean (SE) 1.8 (0.2) 1.6 (0.2) 1.6 (0.1)
Median (range) 1.7 (1.4–2.9) 1.4 (0.9–2.6) (1.5; 1.7)c
Hemoglobin, g/dL
Mean (SE) 12.3 (0.7) 11.6 (0.9) 12.5 (0.9)
Median (range) 13.0 (7.9–14.6) 10.3 (9.0–16.0) (11.6; 13.4) c
Platelet counts, /mm3
Mean (SE) 70,975 (8700.6) 70,067 (7695.5) 69,500 (42,500)
Median (range) 70,500 (42,800–107,000) 70,000 (40,000–103,000) (27,000; 112,000)c
Chitotriosidase activityd, nmol/mg ∙h
Mean (SE) 27,632 (4654.9) 21,023 (8110.4) 28,102 (1763.5)
Median (range) 33,161 (7631–41,201) 15,169 (3035–62,351) (26,338; 29,865)c
CCL18, ng/mLe
Mean (SE) 793.7 (94.8) 899.9 (162.8) 1011.5 (373.5)
Median (range) 810.0 (479–1248) 799.0 (489–1882) (638; 1385)c
CCL18, chemokine (C\\C motif) ligand 18; MN, multiples of normal, where normal spleen volume is 2 mL/kg times body weight (kg) and normal liver volume is 25 mL/kg times body
weight (kg); SE, standard error.
a Baseline values are from the original study (PB-06-001).
b Volume rounded up to 8.0 for Study PB-06-001 inclusion purposes.
c Median not applicable for n = 2.
d Taliglucerase alfa 30 U/kg and 60 U/kg groups, n = 7 for each.
e Taliglucerase alfa 30 U/kg, n = 7.
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Individual patient efﬁcacy results are listed in Supplementary Tables
S1–3. Mean spleen and liver volumes showed continuous decreases
during 60 months of treatment with taliglucerase alfa 30 U/kg and
60 U/kg (Fig. 2). Mean reductions (SE) in spleen volume for the 16 pa-
tients who completed 60months and had organ volumemeasurements
were −8.7 MN (2.0 MN; n = 7) for patients receiving 30 U/kg,
−6.9 MN (0.8 MN; n = 7) for patients receiving 60 U/kg, and
−12.4 MN (5.8 MN; n = 2) for patients who had a dose adjustment;
these represented mean percent reductions (SE) of −56.7% (3.7%),
−67.9% (2.9%), and −61.0% (4.3%) for these groups, respectively.
Mean reductions from baseline to 60 months in liver volumes were
−0.6 MN (0.1 MN; n = 7) for patients receiving 30 U/kg, −0.4 MN
(0.1 MN; n = 7) for patients receiving 60 U/kg, and −0.5 MN
(0.1 MN; n = 2) for patients who had a dose adjustment; these repre-
sented mean percent reductions (SE) of -32.5% (1.9%),−23.3% (7.7%),
and−30.4% (2.4%), respectively.
Mean hemoglobin concentration rose through the ﬁrst 12 months
and remained stable over the ensuing 48 months of therapy with
taliglucerase alfa therapy (Fig. 3). Mean changes (SE) from baseline
to 60 months in hemoglobin concentration were +14.1 mg/dL
(0.9 mg/dL; n = 7) for patients receiving 30 U/kg, +13.9 mg/dL
(0.6 mg/dL; n = 8) for patients receiving 60 U/kg, and +14.3 mg/dL
(0.1 mg/dL; n = 2) for patients who had a dose adjustment; these rep-
resented mean percent changes (SE) of +18.8% (4.8%), +20.5% (5.9%),
and +14.6% (7.8%) for these groups, respectively. Platelet counts rose
continuously in parallel with the continuous improvement in spleen
volume. Mean increases from baseline to 60 months in platelet count
were +31,871/mm3 (14,299/mm3; n = 7) for patients receiving
30 U/kg, +106,800/mm3 (18,967/mm3; n = 8) for patients receiving
60 U/kg, and +34,000/mm3 (18,000/mm3; n = 2) for patients who
had a dose adjustment; these represented mean percent changes (SE)
of +44.8% (20.5%), +168.0% (41.4%), and +52.8% (6.4%), respectively.
Chitotriosidase activity and CCL18 concentration decreased dur-
ing the 60 months of treatment with taliglucerase alfa (Fig. 4). At
month 60, chitotriosidase activity decreased from baseline by a
mean (SE) of −83.1% (4.7%; n = 7) for patients receiving 30 U/kg,Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016−93.4% (1.7%; n = 7) for patients receiving 60 U/kg, and −87.9%
(5.0%; n= 2) for patients who had a dose adjustment; mean percent
decreases from baseline to 60 months in CCL18 concentration were
−66.7% (4.7%; n = 7), −83.3% (3.3%; n = 8), and −78.9% (6.7%;
n = 2), respectively.
Lumbar spine fat fraction was measured at months 48 and 60 for 5
patients (3 receiving 30 U/kg and 2 receiving 60 U/kg) using QCSI [14,
15]. All 5 patients demonstrated increases in lumbar spine fat fraction
from baseline (range 0.13–0.32). At baseline, 1 patient had a fat fraction
N0.23, which increased to 0.46 by month 60. Four patients had lumbar
spine fat fraction ≤0.23 at baseline; by month 48, 3 of these patients
had values ≥0.37, which was maintained through 60 total months of
treatment. The 1 patient who did not achieve a fat fraction ≥0.37 had
the lowest baseline value (0.11) and improved to 0.29 at month 60.
3.2. Safety
Taliglucerase alfawaswell tolerated. AEs occurring during Study PB-
06-007, based on all enrolled patients (N = 19), are summarized in
Table 3. The most common AEs were nasopharyngitis (26.3%; n = 5)
and arthralgia (15.8%; n= 3). The majority of AEs were mild to moder-
ate in intensity. Two severe non–treatment-related AEs were reported
in 2 patients receiving taliglucerase alfa 60 U/kg: a very severe (Grade
4) right hip arthrosis that required surgical artiﬁcial hip implantation
(30-011) and a severe (Grade 3) papillary thyroid carcinoma that ne-
cessitated a total thyroidectomy and left node resection (42-026).
Both of these events were also considered serious AEs; no other serious
AEs were reported. None of the AEs reported during PB-06-007 were
considered to be related to treatment. No patient experienced anaphy-
laxis during Study PB-06-007. One patient (30-009) who experienced
hypersensitivity during PB-06-003 did not receive pre-medication and
did not have a recurrence during PB-06-007.
Most laboratory test values remained normal through study end. No
abnormal values were clinically meaningful or reported as AEs during
the study, with the exception of those for 2 patients (14-027 and 15-
016), which were not considered to be related to treatment. No abnor-
mal ﬁndings were observed in any of the ECG parameters, and no clini-
cally signiﬁcant changes in ECG ﬁndings were noted during the study.), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
Fig. 2.Mean (A) spleen volume and (B) liver volume through 60 total months of treatment with taliglucerase alfa. Organ volumes are expressed as multiples of normal (MN), where
normal spleen volume is 2 mL/kg times body weight (kg) and normal liver volume is 25 mL/kg times body weight (kg). At each time point, values represent the mean based on all
patients with available data who entered Study PB-06-007. Patient 17-033 (60 U/kg) did not have spleen and liver volume data at months 48 and 60 due to refusal to undergo the
magnetic resonance imaging procedure. Patient 40-017 (30 U/kg) and patient 40-018 (60 U/kg) did not have spleen and liver volume data at months 48 and 60 due to study
discontinuation. After 27 totalmonths of treatment, patients 11-014 and42-025had dose adjustments from30U/kg to 45U/kg and 60U/kg, respectively. Error bars denote standard error.
5A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxTwo patients (17-032 and 15-016) had abnormal echocardiography re-
sults; these consisted of left ventricular dysfunction atmonth 60 in 1 pa-
tient and fusion of the right and left coronary cusps, ﬁrst reported
during PB-06-003 and continuing at month 48. Both patients continued
to receive taliglucerase alfa for 60 months and completed the study.
A total of 6 patients reported bone pain during Study PB-06-007. Re-
ports include spine pain (patient 30-008; 30 U/kg), lower back pain (pa-
tient 41-022; 30 U/kg), left knee pain (patient 30-009; 60 U/kg), right
knee pain, left hip pain, and generalized pain in pelvic bones (patient
30-011; 60 U/kg), right knee pain (patient 42-026; 60 U/kg), and inter-
mittent bone pain in the left shin (patient 11-014; dose-adjustment
group). None of these events were reported as treatment-related.Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (20163.3. Antidrug antibodies
Of the patients who entered PB-06-007, 8 had previously tested
positive for immunoglobulin G (IgG) antibodies to taliglucerase alfa
(Supplementary Tables S1 and S2). In PB-06-007, 5 patients tested
positive for IgG antibodies to taliglucerase alfa; all were among
those who previously tested positive in PB-06-003. Neither of the
patients who discontinued Study PB-06-007 tested positive for
IgG antibodies to taliglucerase alfa at any time during all 3 studies.
Of the 5 patients who tested positive for IgG antibodies to
taliglucerase alfa in PB-06-007, 3 (10-028, 15-016, and 30-008)
tested positive and 2 (17-032 and 30-009) tested negative for neu-
tralizing activity based on an in vitro enzymatic activity assay in PB-
06-007. No new treatment-related AEs were reported in patients
who tested positive for anti-taliglucerase alfa IgG antibodies in
PB-06-007.), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
Fig. 3.Mean (A) hemoglobin concentration and (B) platelet count through 60 total months of treatment with taliglucerase alfa. At each time point, values represent themean based on all
patients with available data who entered Study PB-06-007. Patient 40-017 (30 U/kg) and patient 40-018 (60 U/kg) did not have data at months 48 and 60 due to study discontinuation.
After 27 total months of treatment, patients 11-014 and 42-025 had dose adjustments from 30 U/kg to 45 U/kg and 60 U/kg, respectively. Error bars denote standard error.
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Taliglucerase alfa, an ERT approved for treatment of GD, is the ﬁrst
FDA-approved plant cell–expressed recombinant therapeutic protein.
Study PB-06-007was a long-term treatment follow-up of themulticen-
ter, multinational, 2-dose (30 U/kg and 60U/kg) taliglucerase alfa phase
3 pivotal study, PB-06-001, and its extension study PB-06-003,
representing the ﬁnal 21months of the total 60months of taliglucerase
alfa in (initially) treatment-naïve adults with GD. Spleen volume, liver
volume, chitotriosidase activity, and CCL18 concentration decreased
continuously over the 60months of taliglucerase alfa treatment. Platelet
counts increased continuously over the 60months of treatment, andhe-
moglobin concentration rose during the ﬁrst 12 months of therapy and
remained stable through the end of the study. Treatment was well tol-
erated,withmostlymild tomoderate AEs andnoAEs considered related
to treatment.
QCSI measurements of lumbar spine fat fraction in 5 patients
showed that all experienced improvement in this exploratory endpoint.Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016Comparison to data from a Dutch QCSI population study [15] indicated
that 4 patients were at risk for bone complications (≤0.23) at baseline.
Three of these patients achieved levels found to be normal in the
Dutch population (≥0.37) by 48 months of taliglucerase alfa treatment,
which was maintained through 60 total months of treatment. One pa-
tient who did not achieve a level of ≥0.37 by 60 months had the lowest
baselinemeasurement and reached a level of 0.29 by 60months, which
was considered to be above the level for risk of bone complications.
Thus, this exploratory analysis of lumbar spine fat fraction by QCSI of
5 patients indicated that taliglucerase alfa treatment resulted in clinical-
ly meaningful improvements.
The limitations of this study include the small number of patients in
each dose group, which is common for studies involving rare diseases
such as GD. While the patients in the 60 U/kg dose group appeared to
achieve more rapid and profound responses, these observations should
take the small sample size into consideration.
The signiﬁcance of the anti-taliglucerase alfa antibodyﬁndings is un-
clear at this time. In patients with positive results for anti-taliglucerase), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
Fig. 4.Mean percent change in (A) chitotriosidase activity and (B) chemokine (C\\C motif) ligand 18 (CCL18) concentration from baseline through 60 total months of treatment with
taliglucerase alfa. At each time point, values represent the mean based on all patients with available data who entered Study PB-06-007. No chitotriosidase activity data was available
for 1 patient (30-111) in the 60 U/kg dose group who was found to have no chitotriosidase activity at baseline; this patient was excluded from the chitotriosidase analysis and was
followed by the CCL18 assessment. Two patients (40-017, 30 U/kg, and 40-018, 60 U/kg) did not have data at months 48 and 60 due to study discontinuation and were also excluded
from chitotriosidase activity and CCL18 analyses. After 27 total months of treatment, patients 11-014 and 42-025 had dose adjustments from 30 U/kg to 45 U/kg and 60 U/kg,
respectively. Error bars denote standard error.
7A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxalfa IgG or neutralizing antibody assay results, therewas no effect on theTable 3
Adverse events occurring in Study PB-06-007 (N = 19).a
No. of adverse events
(no. of patients) b
Percentage of total adverse events
Total adverse events 73 (15) 100.0
Mild or moderate 71 (15) 97.3
Severe/very severe 2 (2) 2.7
30 U/kg 0 (0) 0.0
60 U/kg 2 (2) 0.0
Seriousb 2 (2) 2.7
Treatment-related 0 (0) 0.0
a Adverse events occurring in extension study PB-06-007 and based on all patients
enrolled in that study (N= 19).
b Right hip arthrosis requiring artiﬁcial hip replacement (patient 30-011) and papillary
thyroid carcinoma requiring thyroidectomy (patient 42-026).
Please cite this article as: A. Zimran, et al., Blood Cells Mol. Diseases (2016efﬁcacy parameters of spleen volume, liver volume, hemoglobin con-
centration, platelet count, or biomarkers based on evaluations of these
parameters from the original study frombaseline to last observation, al-
though 1 patient with anti-taliglucerase alfa antibodies appeared to ex-
perience a decrease in platelet count (30-008; 30 U/kg; decrease from
86,000/mm3 to 64,000/mm3), and another patient experienced a small
increase in liver volume (14-027; 60 U/kg; increase from 1.3 MN to
1.4 MN); however, improvements were observed for all other efﬁcacy
parameters for both of these patients. It should be noted that compari-
son of the incidence of taliglucerase alfa antibodies to that of other prod-
ucts can be misleading and should be approached with caution because
assay results are highly dependent on the sensitivity and speciﬁcity of
each assay and may be inﬂuenced by several factors, including assay
methodology, sample handling, timing of sample collection, concomi-
tant medication, and underlying disease [8].), http://dx.doi.org/10.1016/j.bcmd.2016.07.002
8 A. Zimran et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxx5. Conclusions
Long-term improvements in visceral and hematologic disease pa-
rameters and in biomarkers were observed in 17 treatment-naïve
adult patients with GD during 5 years of treatment with taliglucerase
alfa. These ﬁndings represent long-term continuous evaluation of
taliglucerase alfa in treatment-naïve patients with GD and extend the
clinical efﬁcacy and safety dataset for taliglucerase alfa at 2 dose levels
over a 5-year period. In this study, taliglucerase alfa was well tolerated,
and no new safety concerns emerged.
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